drugset
drugset / Trial / NCT01757197

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

NCT01757197 ↗

Phase 2 Terminated 2 enrolled Weill Medical College of Cornell University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.

Timeline

Start
2013-11-07
Primary completion
2014-06-17
Completion
2014-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous

Indications

No indication recorded.